initi coverag cro
underli fundament skew veli key risk up-tick biopharma
broadli posit cro complex result stabil
improv post challeng end spike cancel boost
multipl book acceler turn page sever entiti
still integr mode post notabl strateg event clear leader emerg
fundament broadli appear reason strong work complex
support msd core growth coupl attract increment margin
activ capit alloc deliv highli visibl double-digit tsr
develop spend acceler modestli pre-clin re-norm
believ pre-clin develop remain healthi albeit sign
suggest normal discoveri post period elev growth late
phase modestli improv market remain notabl robust phase
iv portion contract manufactur secular driver low level
outsourc support hsd dd increas one specter hang
complex remain potenti up-tick biopharma
could potenti caus nt decis make paus compress p/e
ultim view exercis lt need synergi larg
deal like push entiti toward outsourc acknowledg nt reaction
unlik
thing watch biopharma book cadenc fund
debat see normal industri growth rise
ecro mean industri impact biopharma pipelin
shift complex/orphan drug industri continu consolid
industri growth forecast forese core growth rate sustain msd
rang given healthi biotech equiti fund consist clinic trial new start
mix shift high growth area phase iv contract manufactur
model slight acceler develop spend post challeng end
due cancel slight deceler preclin elev level
prior two year main swing factor remain degre larg
scale biopharma outsid unforeseen clinic trial failur could caus
valuat price target across complex impli market cap weight price-to-earnings
termin growth rate dcf primari valuat metric
compar price-to-earnings rang average pleas
note forecast attempt account tax reform relat upsid ep
dcf analysi also adjust updat cash tax rate thu view point
valuat reflect reform pass
downsid risk larg up-tick biopharma result decis make
delay pipelin cancel result growth disloc notabl ramp
cancel given larg scale clinic failur across major categori i/o lead
increas growth volatil continu shift toward pressur margin
pharma debat appropri outsourc model level value-add requir
upsid risk shift e-cro aid cost flexibl ultim result
enhanc trial execut yield step-funct increas penetr biotech
fund pipelin success rate remain robust yield elev level outsourc
spend given primarili virtual model rel multipl continu expand given
highli visibl compound natur financi algorithm busi model scarciti
compani initi iclr outperform
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi coverag contract research
last page report import disclosur regard stock report
tabl content
industri debat normal industri growth
industri debat rise ecro mean industri
industri debat impact shift complex/orphan drug
 bull bear debat thesi
underli fundament remain attract loom up-tick biopharma temper enthusiasm
broadli posit cro complex result stabil improv post
challeng end spike cancel boost multipl book acceler
turn page sever entiti still integr mode post notabl strateg
event clear leader emerg fundament broadli appear reason strong
work complex support msd core growth coupl attract
increment margin activ capit alloc deliv highli visibl double-digit tsr
believ pre-clin develop remain healthi albeit sign suggest
normal discoveri post period elev growth late phase modestli improv
market remain notabl robust phase iv portion contract manufactur
secular driver low level outsourc support hsd dd increas
one specter hang complex remain potenti up-tick biopharma
 could potenti caus nt decis make paus compress p/e
ultim view exercis lt need synergi larg deal
like push entiti toward outsourc acknowledg nt reaction unlik
thing watch biopharma book cadenc fund
rel valuat point balanc slight risk reward across complex
debat normal industri growth
cro industri growth deceler sinc
gain come high growth area like phase iv trial biotech whose fund remain quit robust
total capit rais us eu us bn
 growth high growth area penetr msd
debat rise ecro mean industri
data util key debat post q/im
multipl model exist juri win
recent trend use big data new technolog
access big data set better predict trial outcom
mitig key challeng within industri includ
cancer patient join trial
trial fail reach recruit goal
site fail recruit singl patient
trail delay
trial protocol amend
enrol patient drop
trial cost maintain site
access mm patient ehr
iclr/ibm watson ai trial data
lh/cvd/chiltern access patient lab data
prah/symphoni access script prescrib data
offer average app support clinic trial activ
applications/tech use trial recruit patient
natur friction exist transform industri overal
howev sever hurdl remain widespread use
outsid risk-bas monitor econs form
get fda board outsid data use risk-bas
monitor econs fda yet offer guidelin
dispar data sourc unstructur standard
data across sourc make difficult draw conclus
patient privaci use data recruit violat patient
confidenti dr use data approach patient
data ownership own data patient/cro/pharma co
secur cloud-bas tech vulner cyber threat
ad complex caus downstream delay
add anoth step releas data
benefit industri
like mid lt w/
winner co
use big data/tech
debat impact shift complex drug
biolog drug account larger portion pipelin
clinic trial becom complex
increas average metric
lead higher cancel across industri
data iclr prxl
cancel begin backlog
re-stat backlog includ
complex drive demand qualiti core held back convers headwind
industri player favor bolt-on sever compani capac larger strateg acquisit
capac market cap
market still fragment outsid larg public
rest
expect
continu tuck-in
wouldnt surpris
given sever player
capac appetit
strateg deal
valuat re-rat follow mix period perform
cro multipl reflect transit strong cash flow busi modest margin expans solid msd growth
risk point balanc risk/reward profil phase iv strength vs potenti biopharma
larg up-tick biopharma result decis make delay pipelin cancel result growth disloc
notabl ramp cancel given larg scale clinic failur across major categori i/o lead increas growth volatil
continu shift toward pressur margin pharma debat appropri outsourc model level value-add requir
shift e-cro aid cost flexibl ultim result enhanc trial execut yield step-funct increas penetr
fund pipelin success rate remain robust yield elev level outsourc spend given primarili virtual model
rel multipl continu expand given highli visibl compound natur financi algorithm busi model scarciti
chart evercor isi factset
bull bear debat skew favor remain select
move hurt margin
invest market
attract secular grower w/ superior management execut challeng nt
slowdown core pharma
best-in-class execut meet balanc sheet option must-own long-
pharma servic technolog disruptor w/ super execut capit
initi pt
last page report import disclosur regard stock report
tabl content
debat concern recent deceler rm demand
debat one best tuck-in acquir univers
debat drive broad strength manufactur support
point differenti vs st
 conclus initi growth re-norm
rm strong cash biz mfg supp dsa drive growth
earli stage cro focu discoveri earli stage
develop manufactur servic pharma
biotech well gov academ custom
thesi re-norm core growth occur
next qs elev level rm rebas limit
rate valuat pt pt
ebitda vs average
price-to-earnings vs average
risk materi slowdown biotech relat fund
up-tick would yield growth pressur
notabl overweight us biotech exposur
join held varieti role
built nich provid lead cro
previous ceo galapago servic
join research scientist
david johst evp hr gc cao yr
serv attorney boston hale dorr prrior
debat concern recent deceler rm
concern rm declin despit strong market share
price key strategi off-set declin model volum
rm declin despit sell everi model
rm volum continu declin due rs facil
increas focu china complex model servic
china growth driver
china us yr ago
nascent unsophist real
competit us w/ peopl want high
growth complex model
model complex valu model
sold significantli increas
grow demand human model
increas focu rm servic
svc cont grow see
continu grow lsd jeffco london
volum outsid china declin past
year judici use model jeffco
 facil big drug compani go
facil go
price key strategi help off-set volum declin
alway abl charg premium high
qualiti clean model clear virus
bacteria continu ad
taken smaller price penetr market
work well
declin off-set
growth area lead
debat one best tuck-inn univers
deliv bp core per year
last deal consid strateg size
leav plenti bs option
key strategi deliv low dd ep growth
capac market cap
proven integr chop fragment industri help deliv ldd ep growth
debat drive strength manufactur support
mfg support grown dd past yr
crl portfolio address everi aspect bn market
total rev ebitda margin
microbi solut qc test servic steril non-
steril applic focus high-valu market pharma
pt system instal horsesho crab blood
need cartridg vs tradit method
celsi rapid microbi detect time vs
clinic commerci mfg final drug releas
dd growth lt outlook support secular tw
increas biologics/biosimilar product pharma
stream offer bring global
player full suit qc test capabl
fragment market global player tier ton small
busi mfg
support key growth
profit driver go
model summari point differenti vs street
swing factor dsa mfg offset rm hw fund strength bia capit alloc
point differenti
view core
shift all-in oi growth
ep st w/
leverag main delta
debt level trend
step-up
street underestim compound natur model core revenu slow nt
million except per share data fy end decemb model organ safeti organ organ organ gp less total model safeti op less ep share inc net inc price-to-earnings prem disc januari
valuat rebas elev growth profil hsd
trade clinic despit exposur favor stabl part drug dev valu chain
risk point balanc risk reward profil consist execut secular growth vs rm slowdown
potenti down-tick biotech relat fund yield pressur core across franchis limit degre ep compound
materi increas biopharma post reform result slow decis make drive near-term multipl compress
shift strategi amongst earli phase competitor bring sizeabl amount suppli on-line lead pressur tox price
continu elev biotech fund result superior hsd core growth profil sustain recent elev multipl rang
up-tick tuck-in activ allow all-in growth remain doubl digit despit modest deceler core profil
biopharma yield need aggress synergi ramp ultim lead materi up-tick outsourc achiev target
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi pt upsid
attract secular grower w/ superior management execut challeng nt slowdown core pharma
bullish share given strong core perform synergi
captur wil continu tuck-in activ lead consist ep upsid surpris
manag continu build histor track record execut deliv anoth
year dd ep perform although slight deceler rm caus volatil
enter see core growth begin re-norm toward msd hsd due
challeng comp rm restructur tuck-in activ slightli mute
coupl w/ modest tax reform relat upsid headwind strong vc
gain prior year see ep beat bias engin gain steam
furthermor see modestli elev level near-term risk up-tick pharma
could creat nt volatil also lt opportun given need synergi captur
thu ultim conflict long-term remain remark bright given
multipl secular tailwind manag done tremend job valu creation
prefer stanc see initi guidanc play monitor trend
look opportun becom construct valuat becom compel
valuat current fair mind given slight deceler growth modest macro
uncertainti also contend downsid risk mitig notabl strong yield
given dynam see risk reward balanc thu initi share rate
thing watch rm restructur financ pace tuck-in
initi outperform pt
last page report import disclosur regard stock report
tabl content
debat bottom busi reset
debat strong non-pf busi trend
debat refrain splashi posit neg
point differenti vs st
iv valuat risk pharma vs consist
 conclus initi o/p best class execut
full servic global cro w/ phase ii iv focu
lead late stage cro focus strateg
develop management analysi program
support compound select phase i-iv clinic studi
strong cost manag capit alloc allow
best-in-class compound w/ upsid b/ usag
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
risk notabl up-tick larg scale pharma
result book disrupt multipl compress
rest
outsiz exposur develop region o/w europ
highli skill team w/ strong record execut
debat bottom busi reset
boost core msd mid-teen biz
growth declin project roll-off cancel
iclr select
vendor lead rev
peak total
rev
lead concern appropri concentr
precipit drop assum run rate
key question investor mind
appropri level concentr go forward
long declin weigh growth
management claim steadi state seem reason
concentr decreas
 repres
backlog year ago seem
reason steady-st expect
translat run-rat go forward
headwind reset nearli w/ concentr manag level lt
debat strong non-pf busi trend
respons hw management focus grow ex- biz lead hsd/low-dd growth biz past qs
ex-pf book trend way corp averag
new biz come small-mid size client
rest client
elev ex- book-to-bil offset declin support futur growth
debat refrain splashi
recent cro focus build scale scope
iclr portfolio built organ w/ bolt-on
top rev
bolt-on w/ focus clinic
research consult outcom
mapi biggest deal past yr
free management distract allow focu execut
sub-optimal bs util address
histori support low risk approach balanc sheet optim still possibl
model summari point differenti vs street
swing factor ex-pf book cadenc pace tuck-in degre larg scale pharma
point differenti
optim fx
tailwind
ep st w/
capit alloc
main delta off-set
leverag level
iclr could prove teen compound b/ increasingli util tuck-in
million except per share data fy end decemb organ ex-pf organ organ organ gp less total op less ep share inc net inc price-to-earnings prem disc januari
valuat re-rat choppi gener
iclr growth reacceler recogn year valuat trade group average
risk point favor risk reward profil superior execut vs potenti step pharma
larg scale pharma could lead disrupt decis make notabl downshift nt book momentum
strateg decis sizeabl data asset could prove disadvantag access sourc becom limit challeng
currenc volatil could imped manag abil properli manag cost structur sever limit profit growth overal
materi cancel due earli failur mis-execut could disrupt momentum tarnish clinic reput
notabl downshift biotech relat fund could slow invest fast grow segment clinic trial develop
wage inflat cra due market demand well underli macro shift could limit growth pressur margin
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per iclr perpetu growth valu enterpris enterpris valu januari
conclus initi outperform pt upsid
best-in-class execut meet balanc sheet option must-own long-term ep compound
bullish share icon given expect recoveri non-
busi well continu strong execut cost improv capit alloc
manag continu deliv year despit headwind result materi
inflect share signific new busi momentum begin enter
strong book show allow core growth recov given competitor
distract due sizabl see opportun upsid growth thereaft
furthermor concentr manag level believ multipl
continu upward trend best-in-class execut yield uniqu teen ep compound
help support continu visibl compound strong cost manag
team shown uncanni abil adjust opex nearli demand environ possibl
one major swing factor ep growth remain b/ util compani
gotten aggress via share repurchas like remain activ tuck-in front
would see leverag slowli creep higher time believ elev level ep
growth teen could result multipl return notabl premium vs peer
major risk forese share possibl notabl up-tick pharma
 although belief would ultim prove posit given synergi need
given dynam see risk reward favor thu initi share o/p rate
thing watch book cadenc ex omx trajectori pharma activ
initi outperform pt
follow leader
last page report import disclosur regard stock report
